South San Francisco Biotech Lycia Files for IPO

The South San Francisco-based firm aims to raise up to $264.6 million in its upcoming public market debut.

Updated on Oct. 20, 2026 in Biotech

Bold vector illustration featuring stylized molecular protein structures and geometric growth bars, representing a biotech firm's public market debut. — South San Francisco-based Lycia Therapeutics has filed for an IPO, targeting a valuation of nearly $938 million on the Nasdaq exchange. AI Illustration. Upload story photo >

Live Poll

Do you believe now is a good time to invest in new biotech company stock offerings?

Lycia Therapeutics has filed for an initial public offering in the United States, targeting a company valuation of $937.7 million. The biotech firm plans to list on the Nasdaq exchange under the ticker symbol LYCA.

Why it matters

The offering is designed to raise up to $264.6 million in capital through the issuance of 14.7 million shares. This move underscores the company's efforts to fund its operations and expansion as it enters the public market.

Lycia Therapeutics is offering 14.7 million shares at a price range between $16 and $18 per share. The company has engaged Jefferies, TD Cowen, Evercore ISI, and Guggenheim Securities as joint book-running managers.

The players

Lycia Therapeutics

This biotechnology company is headquartered in South San Francisco and focuses on drug discovery.

Jefferies

This global financial services company is serving as a joint book-running manager for the offering.

Nasdaq

This American stock exchange serves as the intended primary listing platform for the company.

The details

The South San Francisco-based company is positioning itself for a debut on the Nasdaq exchange to support its ongoing development goals. Its entry follows a week of activity in the sector that saw similar companies complete their own public offerings.

October 12-16, 2026: City Therapeutics and Iambic Therapeutics held their public offerings.
October 20, 2026: Lycia Therapeutics announced its IPO valuation target.

The Tech Race

The filing by Lycia Therapeutics follows the surge in biotech sector IPOs during mid-October 2026. This activity highlights a rapid period of market entry for South San Francisco companies seeking to secure public funding.

Investors can monitor the IPO process as the company prepares to list its shares on the Nasdaq exchange. The offering will dictate future capital availability for the company to develop its research pipeline.

The takeaway

This filing represents a significant milestone in Lycia Therapeutics' corporate trajectory. Investors looking to enter the biotech space should track the company's valuation metrics against established benchmarks.